+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunotherapy Drugs Market by Therapy Type (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors), Indication (Blood Cancer, Breast Cancer, Lung Cancer), Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2030- Product Image
Immunotherapy Drugs Market by Therapy Type (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors), Indication (Blood Cancer, Breast Cancer, Lung Cancer), Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2030- Product Image
Sale

Immunotherapy Drugs Market by Therapy Type (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors), Indication (Blood Cancer, Breast Cancer, Lung Cancer), Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889000
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immunotherapy drugs market is rapidly advancing, propelled by innovation in treatment technologies and a growing emphasis on precision oncology. Leaders in healthcare, research, and biopharma are recalibrating strategies to remain competitive and address evolving patient needs in this dynamic, global landscape.

Market Snapshot: Immunotherapy Drugs Market Growth and Outlook

The Immunotherapy Drugs Market grew from USD 196.96 billion in 2024 to USD 222.59 billion in 2025. It is expected to continue growing at a CAGR of 12.41%, reaching USD 397.54 billion by 2030. This strong trajectory reflects the widespread adoption of immune-based therapies and the expanding role of innovative treatment mechanisms across oncology care. Market expansion is being supported by advancements in cell therapies, regulatory adaptation, and a heightened focus on targeted interventions, making immunotherapy a central element in modern cancer management.

Scope & Segmentation

This comprehensive market report delivers a detailed analysis of the immunotherapy landscape, enabling executives to benchmark strategic opportunities across varied sub-sectors and geographies.

  • Therapy Types: Adoptive cell therapies (including CAR-T, NK cell, TCR-T), cancer vaccines (dendritic cell, DNA, peptide), checkpoint inhibitors (CTLA-4, PD-1, PD-L1), cytokines (colony stimulating factors, interferons, interleukins), and oncolytic virus therapies (adenovirus, herpesvirus, reovirus).
  • Indications: Blood cancers (acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, lymphoma), breast cancer (hormone receptor positive, triple negative), lung cancer (non-small cell, small cell), melanoma (cutaneous, uveal).
  • Routes of Administration: Intratumoral, intravenous, and subcutaneous delivery methods.
  • End Users: Hospitals, oncology clinics, and specialized treatment centers, considering varied clinical and operational capacities.
  • Mechanism of Action: Active immunotherapy (cancer vaccines, oncolytic viruses), combination therapies, and passive immunotherapy (adoptive cell therapy, checkpoint inhibitors, monoclonal antibodies).
  • Regional Coverage: Americas (United States by state, Canada, Mexico, Brazil, Argentina), Europe Middle East & Africa (20+ nations including UK, Germany, France, Russia, Turkey, South Africa), and Asia-Pacific (China, India, Japan, Australia, and key Southeast Asian markets).
  • Key Companies: Merck & Co., Bristol-Myers Squibb, F. Hoffmann-La Roche, AstraZeneca, Novartis, Johnson & Johnson, Gilead Sciences, Pfizer, Sanofi, Amgen.

Key Takeaways for Decision-Makers

  • Immunotherapy is moving from niche to mainstream, shifting oncology clinical paradigms and driving personalized treatment pathways.
  • Technological advances such as CRISPR cell editing and AI-driven antigen discovery are expediting drug development and fueling innovation.
  • Global and regional regulatory shifts are enabling faster approvals and a broader range of clinical endpoints, enhancing adaptability across markets.
  • Manufacturing improvements, including decentralized production, are advancing scalability and accelerating therapy delivery to patients.
  • Strategic partnerships and diversified portfolios distinguish leading enterprises, strengthening supply chain resilience and expanding commercialization versatility.
  • Data-driven approaches—such as integrated diagnostics and outcome-based models—support value-based healthcare and improved real-world impact.

Tariff Impact: US 2025 Measures on Supply Chain & Access

Cumulative United States tariff measures imposed in 2025 are influencing the immunotherapy supply chain on multiple levels. Increased duties on critical raw materials and bioreactor technologies are prompting pharma companies to reassess supplier portfolios and strengthen regional production. This drives new trade collaborations, longer investment cycles, and a focus on procurement stability. In this context, value-based contracting and shared-risk models are gaining ground to ensure therapy affordability and drive sustainable adoption.

Methodology & Data Sources

The research combines qualitative interviews with leading clinicians, manufacturing executives, policy experts, and patient advocates, alongside a rigorous review of peer-reviewed literature, patent trends, and regulatory filings. Data triangulation and consultation with industry advisory boards ensure findings are relevant and actionable.

Why This Report Matters

  • It equips executives with a data-driven benchmark for strategic decision-making in a rapidly evolving sector.
  • The report highlights regional shifts, competitive dynamics, and innovation trends essential for shaping pipeline success and market resilience.

Conclusion

This analysis empowers senior leaders to leverage emerging technologies, align with regulatory changes, and optimize commercial models. Stakeholders can confidently design resilient strategies that accelerate patient access and growth in the immunotherapy drugs market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of bispecific antibodies targeting dual tumor antigens in solid tumors
5.2. Expansion of CAR-T therapies beyond hematologic malignancies into solid tumor indications
5.3. Integration of immune checkpoint inhibitor biosimilars to improve affordability across emerging markets
5.4. Development of tumor microenvironment modulators to enhance T-cell infiltration in resistant tumors
5.5. Personalized neoantigen vaccine platforms combining genomic sequencing with AI-driven epitope prediction
5.6. Implementation of combination therapies integrating oncolytic viruses with PD-1 and CTLA-4 inhibitors
5.7. Growth of allogeneic off-the-shelf natural killer cell products to streamline manufacturing timelines
5.8. Regulatory approvals accelerating for next-generation IL-2 and IL-15 cytokine therapies with improved safety profiles
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immunotherapy Drugs Market, by Therapy Type
8.1. Introduction
8.2. Adoptive Cell Therapy
8.2.1. Car-T Therapy
8.2.2. Nk Cell Therapy
8.2.3. Tcr-T Therapy
8.3. Cancer Vaccines
8.3.1. Dendritic Cell Vaccines
8.3.2. Dna Vaccines
8.3.3. Peptide Vaccines
8.4. Checkpoint Inhibitors
8.4.1. Ctla-4 Inhibitors
8.4.2. Pd-1 Inhibitors
8.4.3. Pd-L1 Inhibitors
8.5. Cytokines
8.5.1. Colony Stimulating Factors
8.5.2. Interferons
8.5.3. Interleukins
8.6. Oncolytic Virus Therapy
8.6.1. Adenovirus Based
8.6.2. Herpesvirus Based
8.6.3. Reovirus Based
9. Immunotherapy Drugs Market, by Indication
9.1. Introduction
9.2. Blood Cancer
9.2.1. Acute Lymphoblastic Leukemia
9.2.2. Acute Myeloid Leukemia
9.2.3. Chronic Lymphocytic Leukemia
9.2.4. Lymphoma
9.3. Breast Cancer
9.3.1. Hormone Receptor Positive
9.3.2. Triple Negative
9.4. Lung Cancer
9.4.1. NonSmallCell Lung Cancer
9.4.2. SmallCell Lung Cancer
9.5. Melanoma
9.5.1. Cutaneous Melanoma
9.5.2. Uveal Melanoma
10. Immunotherapy Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intratumoral
10.3. Intravenous
10.4. Subcutaneous
11. Immunotherapy Drugs Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Oncology Clinics
11.4. Specialized Centers
12. Immunotherapy Drugs Market, by Mechanism Of Action
12.1. Introduction
12.2. Active Immunotherapy
12.2.1. Cancer Vaccines
12.2.2. Oncolytic Virus Therapy
12.3. Combination Therapies
12.4. Passive Immunotherapy
12.4.1. Adoptive Cell Therapy
12.4.2. Checkpoint Inhibitors
12.4.3. Monoclonal Antibodies
13. Americas Immunotherapy Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immunotherapy Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immunotherapy Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Bristol-Myers Squibb Company
16.3.3. F. Hoffmann-La Roche Ltd
16.3.4. AstraZeneca PLC
16.3.5. Novartis AG
16.3.6. Johnson & Johnson
16.3.7. Gilead Sciences, Inc.
16.3.8. Pfizer Inc.
16.3.9. Sanofi S.A.
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. IMMUNOTHERAPY DRUGS MARKET: RESEARCHAI
FIGURE 26. IMMUNOTHERAPY DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. IMMUNOTHERAPY DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. IMMUNOTHERAPY DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 205. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 206. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 207. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 208. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 209. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 210. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 211. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 212. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 213. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 214. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 215. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 216. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 217. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 220. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 221. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 222. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 223. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 224. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 225. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 226. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 227. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 232. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 233. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 234. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 235. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 236. CANADA IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 237. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 238. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 239. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 240. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 241. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 242. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 243. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 246. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 247. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 248. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 249. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 252. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 253. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 254. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 255. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 256. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 257. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 258. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 259. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 264. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 265. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 266. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 267. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 268. MEXICO IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 328. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 329. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 330. ARGENTINA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD M

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Immunotherapy Drugs market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 222.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 397.54 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Cancer Immunotherapy Drugs Market by Mechanism Of Action, Cancer Type, Treatment Line, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast 2025-2030 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2025 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cancer Immunotherapy: Technologies and Global Markets - Product Image

Cancer Immunotherapy: Technologies and Global Markets

  • Report
  • 203 Pages
  • Global
From
Cancer Immunotherapy Market Report 2025 - Product Image

Cancer Immunotherapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Immunotherapy Market

Immunotherapy is a type of treatment used to treat immune disorders, such as allergies, asthma, and autoimmune diseases. It works by stimulating the body's own immune system to fight off disease-causing agents. Immunotherapy drugs are designed to target specific parts of the immune system, such as T-cells, B-cells, and cytokines. These drugs can be used to treat a variety of conditions, including cancer, HIV/AIDS, and rheumatoid arthritis. Immunotherapy drugs are typically administered through injections, infusions, or oral medications. They can also be used in combination with other treatments, such as chemotherapy or radiation therapy. The goal of immunotherapy is to reduce the severity of symptoms and improve the patient's quality of life. The immunotherapy market is a rapidly growing sector of the pharmaceutical industry. Companies in this market are focused on developing new treatments and therapies to treat immune disorders. Some of the major players in this market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.